2CUREX — 2cureX AB Share Price
- SEK221.07m
- SEK167.08m
Momentum
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | |||
EPS Growth (f) | |||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | |||
Price to Tang. Book | |||
Price to Free Cashflow | |||
Price to Sales | |||
EV to EBITDA |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | |||
Return on Equity | |||
Operating Margin |
Financial Summary
Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | SEKm | n/a | 0.05 | n/a | n/a | n/a | 4 | 22 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Directors
- Povl-Andre Bendz (56)
- Fernando Andreu
- Ole Thastrup DCE (65)
- Kenneth Johansen
- Juergen Kupper (53)
- Grith Hagel (59)
- Henrik Harling
- Maarten van der Linden
- Camilla Huse Bondesson
- Joergen Drejer (65)
- Timm-H. Jessen (55)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- January 1st, 1970
- Public Since
- November 24th, 2017
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 14,856,600
- Address
- c/o Mazars SET Revisionsbyra AB, Box 159, LANDSKRONA, 26122
- Web
- https://www.2curex.com/
- Phone
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Latest News for 2CUREX
Upcoming events for 2CUREX
Similar to 2CUREX
BIOVICA INTERNATIONAL ORD
OMX Nordic Exchange Stockholm
Q-LINEA ORD
OMX Nordic Exchange Stockholm
SENZAGEN ORD
OMX Nordic Exchange Stockholm
SPAGO NANOMEDICAL ORD
OMX Nordic Exchange Stockholm
FAQ
As of Today at 11:29 UTC, shares in 2cureX AB are trading at SEK14.88. This share price information is delayed by 15 minutes.
Shares in 2cureX AB last closed at SEK14.88 and the price had moved by -29.81% over the past 365 days. In terms of relative price strength the 2cureX AB share price has underperformed the FTSE Global All Cap Index by -45.13% over the past year.
There is no consensus recommendation for this security.
2cureX AB does not currently pay a dividend.
2cureX AB does not currently pay a dividend.
2cureX AB does not currently pay a dividend.
To buy shares in 2cureX AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK14.88, shares in 2cureX AB had a market capitalisation of SEK221.07m.
Here are the trading details for 2cureX AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: 2CUREX
Based on an overall assessment of its quality, value and momentum 2cureX AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 2cureX AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -52.22%.
As of the last closing price of SEK14.88, shares in 2cureX AB were trading -20.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 2cureX AB.
2cureX AB's management team is headed by:
- Povl-Andre Bendz -
- Fernando Andreu -
- Ole Thastrup - DCE
- Kenneth Johansen -
- Juergen Kupper -
- Grith Hagel -
- Henrik Harling -
- Maarten van der Linden -
- Camilla Huse Bondesson -
- Joergen Drejer -
- Timm-H. Jessen -
We do not have data on 2cureX AB's shareholders